AUS
NZ
UK
CA
USA
IND
Celestica (TSX) Stock Soared 289% in the Last Year: Is the Growth Over or Just Beginning?
Investors often wonder if they've missed out on a booming stock. Celestica (TSX:CLS), a key player in the electronics manufacturing services (EMS) industry, has captured significant attention. With shares surging by 289% in the last year alone, the pressing question is: Is it too late to buy Celestica stock? Let's analyze the data and earnings to find out.
Recent Performance
Celestica has delivered remarkable performance over the past year. The latest financial reports reveal substantial appreciation in stock value, fueled by strong earnings and strategic growth moves. For the fiscal year 2023, the company reported a revenue of US$7.1 billion, a 12% increase from the previous year. This surge was driven by heightened demand in sectors such as aerospace, defense, and healthcare.
Earnings performance is a critical indicator of potential. In the first quarter (Q1) of 2024, Celestica posted an earnings per share (EPS) of US$0.44, surpassing analysts’ expectations by US$0.06. The company's net income for the same period was US$56.7 million, up from US$45.3 million in Q1 2023. This positive trend highlights Celestica’s operational efficiency and market opportunity capitalization.
Growth Drivers
What’s fueling this impressive growth? Several factors. Celestica has diversified its offerings beyond traditional EMS, stepping into design and engineering services, supply chain management, and after-market services. This diversification has broadened its market reach and reduced reliance on a single revenue stream.
The acquisition of PCI Private Limited, a Singapore-based EMS company, has significantly enhanced Celestica’s capabilities in high-growth markets. This acquisition is expected to add approximately US$330 million in annual revenue, boosting Celestica’s competitive edge.
Additionally, Celestica’s focus on sectors like aerospace, defense, and healthcare positions it to benefit from rising demand in these industries. The aerospace and defense sector, for instance, is projected to grow at a compound annual growth rate (CAGR) of 5.6% from 2023 to 2028, presenting strong growth potential for Celestica.
Looking Ahead
Despite recent gains, Celestica’s stock remains attractively valued. The stock trades at a forward price-to-earnings ratio of 22.91, relatively lower than its peers, suggesting it is still undervalued and offering potential upside for investors.
The broader market conditions also favor Celestica. The global EMS market is expected to grow at a CAGR of 7.5% over the next five years, driven by the increasing complexity of electronic products and the trend of outsourcing among OEMs (original equipment manufacturers). With its strong market position and diverse service offerings, Celestica is well-positioned to capitalize on these trends.
Bottom Line
While Celestica’s stock has experienced significant gains over the past year, data and earnings performance indicate it’s not too late to buy. The company’s robust financial health, strategic growth initiatives, and favorable market conditions suggest substantial upside potential remains. For investors seeking to add a solid player in the EMS industry to their portfolio, Celestica offers a compelling opportunity.
